Sign in

CIK 0001880438 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
820606654
Phone
(650) 331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
Open-market buys, last 90 days
$11,602
in 1 filing
Open-market sales, last 90 days
$117,428
in 4 filings, $104K under 10b5-1 plans

Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 94 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-03-19 Spigelman Melvin K Director Returned to the company · Stock Option (right to buy) −23,742 0
2026-03-19 Readnour Robin Shane Director Grant or award · Stock Option (right to buy) +20,724 20,724
2026-03-19 Readnour Robin Shane Director Returned to the company · Stock Option (right to buy) −20,724 0
2026-03-19 Readnour Robin Shane Director Grant or award · Stock Option (right to buy) +23,742 23,742
2026-03-19 Readnour Robin Shane Director Returned to the company · Stock Option (right to buy) −23,742 0
2026-03-19 Easom Eric Chief Executive Officer Grant or award · Stock Option (right to buy) +249,999 249,999
2026-03-19 Easom Eric Chief Executive Officer Returned to the company · Stock Option (right to buy) −249,999 0
2026-03-19 Easom Eric Chief Executive Officer Grant or award · Stock Option (right to buy) +225,000 225,000
2026-03-19 Easom Eric Chief Executive Officer Returned to the company · Stock Option (right to buy) −225,000 0
2026-03-19 Easom Eric Chief Executive Officer Grant or award · Stock Option (right to buy) +267,650 267,650
2026-03-19 Easom Eric Chief Executive Officer Returned to the company · Stock Option (right to buy) −267,650 0
2026-03-03 Williams Sarah Joanne Principal Accounting Officer Sale −327 $1.06 $347 66,848
2026-02-20 Eizen Joshua M See Remarks Grant or award +50,000 207,499
2026-02-20 Eizen Joshua M See Remarks Grant or award · Stock Option (right to buy) +100,000 100,000
2026-02-20 Day Lucy Chief Financial Officer Grant or award +38,000 118,363
2026-02-20 Day Lucy Chief Financial Officer Grant or award · Stock Option (right to buy) −77,000 77,000
2026-02-20 Williams Sarah Joanne Principal Accounting Officer Grant or award +48,375 67,175
2026-02-20 Easom Eric Chief Executive Officer Grant or award +112,250 368,630
2026-02-20 Easom Eric Chief Executive Officer Grant or award · Stock Option (right to buy) +224,500 224,500
2026-02-20 Chanda Sanjay Chief Development Officer Grant or award +38,000 118,823

Page 5 of 10 · 191 trades